Drugs / 18F-AlF-NOTA-neurotensin
18F-AlF-NOTA-neurotensin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03516045 | Apr 2018 → Dec 2019 | prostate cancer | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-AlF-NOTA-neurotensin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03516045 ↗ |
| Modality | Diagnostic / imaging agent | “18F-AlF-NOTA-neurotensin positron emission tomography / computed tomography (PET/CT)” NCT03516045 ↗ |